These updates demonstrate an intense interest in Thermo Fisher Scientific TMO. The company's recent activities include the completion of the $8.875B Clario acquisition, strategic partnership with AIM ImmunoTech on cancer research, and the opening of a Cryo-Electron Microscopy Drug Discovery Center in South San Francisco. Key investors such as Generate Investment Management Ltd and Eagle Rock Investment Company LLC have upped their stakes, while others like DAVENPORT & Co LLC and Professional Advisory Services Inc. trimmed their holdings. Thermo Fisher's earnings reports have exceeded expectations, and its stock has been rated 'Moderate Buy' by analysts. On the downside, the company's shares seem to be experiencing some volatility, with price weakness noticed. The firm's 2026 profit forecast is lower than estimates due to anticipated research funding cuts. However, investors remain bullish given TMO's market trends and developments.
Thermo Fisher Scientific TMO News Analytics from Wed, 23 Jul 2025 07:00:00 GMT to Sat, 28 Mar 2026 10:41:29 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor -2
